https://www.enterair.pl/slot-gacor/

CHRONIC HEPATITIS C IN THE RUSSIAN FEDERATION AFTER STARTING THE HCV ELIMINATION PROGRAM

  • A. A. Dzemova Saint-Petersburg State Pediatric Medical University, Saint Petersburg, the Russian Federation; Saint Petersburg Pasteur Institute, Saint Petersburg, the Russian Federation http://orcid.org/0000-0002-3683-7860
  • R. A. Ganchenko Saint-Petersburg State Pediatric Medical University, Saint Petersburg, the Russian Federation
  • G. F. Trifonova Saint Petersburg Pasteur Institute, Saint Petersburg, the Russian Federation
  • E. V. Esaulenko Saint-Petersburg State Pediatric Medical University, Saint Petersburg, the Russian Federation; Saint Petersburg Pasteur Institute, Saint Petersburg, the Russian Federation http://orcid.org/0000-0003-3669-1993
Keywords: chronic viral hepatitis C, WHO strategy, prevalence, incidence

Abstract

Background. Five years have passed since the adoption of the strategy for the elimination of viral hepatitis. It is necessary to take stock of the first results. Objective – to assess the dynamics of the epidemic process of CHC and the clinical manifestations of the disease during the period of 2015-2019. Material and methods. The article analyzes the data from the state statistical reporting of infectious diseases in the Russian Federation (RF), from the reference-center for the monitoring of viral hepatitis, from statistical tables compiled at Methodological and Research Center for Epidemiological Surveillance of Viral Hepatitis under Pasteur Institute of Epidemiology and Microbiology. The data from the Federal register of patients with viral hepatitis were used. The article analyzes our own experience of observing 555 patients with HCV at different stages of the disease. Results. In 2015–2019, CHC incidence in the RF decreased by 20% (30,90/0000- in 2019, 38,00/0000– in 2015). The total number of people with CHC is increasing (in 2015 – 562 622 people, in 2019 – 635372). It is estimated that only 20% of those infected are under surveillance. The death rate from CHC remains high. The proportion of patients with an advanced stage of CHC is about 20%. The proportion of decompensated cirrhosis decreased by 8%. In recent years, government funding for the treatment has increased, but only about 8% of all registered CHC patients are covered by the therapy. Conclusions. In the RF the WHO strategy targets have not been achieved by 2020. That’s why it’s important to develop a strategy to counter the spread of HCV for the period up to 2030.

References

World Health Organization. Global health sector strategy on viral hepatitis 2016-2021 [Internet]. Available from: http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/ru/ (Russian).

World Health Organization. Global Hepatitis Report 2017 [Internet]. Geneva: World Health Organization; 2017. Available from: https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf?sequence=1.

European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol. Hepatol. 2017;2(5):325-336. https://doi.org/10.1016/S2468-1253(17)30045-6.

POLARIS observatory [Internet]. Available from: https://cdafound.org/dashboard/polaris/dashboard.html

Rospotrebnadzor. Ob utverzhdenii sanitarno-jepidemiologicheskih pravil SP 3.1.3112-13 “Profilaktika virusnogo gepatita S”. Postanovlenie N 58 (оct. 22, 2013) [Internet]. Available from: http://docs.cntd.ru/document/499056593 (Russian).

Pimenov NN, Komarova SV, Karandashova IV, Tsapkova NN, Volchkova EV, Chulanov VP. Gepatit С i ego ishody v Rossii: analiz zabolevaemosti, rasprostranennosti i smertnosti do nachala programmy jeliminacii infekcii [Hepatitis С and its outcomes in Russia: analysis of incidence, prevalence and mortality rates before the start of the programme of infection elimination]. Infekcionnye bolezni [Infectious diseases]. 2018;16(3):37-45. https://doi.org/10.20953/1729-9225-2018-3-37-45. (Russian).

Mikhaylov MI, Yushchuk ND, Malinnikova EYu, Kyuregyan KK, Isaeva OV, Znoyko OO, Klimova EA. Proekt programmy po kontrolju i likvidacii virusnyh gepatitov kak problemy obshhestvennogo zdorovja v Rossijskoj Federacii [The design of the program for control and elimination of viral hepatitis as public health problem in the Russian Federation]. Infekcionnye bolezni: novosti, mnenija, obuchenie [Infectious diseases: news, views, education]. 2018;7(2):52-58. https://doi.org/10.24411/2305-3496-2018-12005. (Russian).

Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. J. Hepatology. 2008;48(2):418-431. https://doi.org/10.1002/hep.22375.

Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE; HALT-C Trial Group. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011;54(2):396-405. https://doi.org/10.1002/hep.24370.

Xu F, Moorman AC, Tong X, Gordon SC, Rupp LB, Lu M, Teshale EH, Spradling PR, Boscarino JA, Trinacty CM, Schmidt MA, Holmberg SD, Holmberg SD, Teshale EH, Spradling PR, Moorman AC, Xing J, Tong X, Xu F, Gordon SC, Nerenz DR, Lu M, Lamerato L, Wang Y, Rupp LB, et al. All-cause mortality and progression risks to hepatic decompensation and hepatocellular carcinoma in patients infected with hepatitis C virus. Clin. Infect. Dis. 2015;62(3):289-297. https://doi.org/10.1093/cid/civ860.

Sukhoruk AA, Gerasimova OA, Esaulenko EV. Cirroz pecheni kak ishod hronicheskogo gepatita С [Liver cirrhosis as a result of chronic hepatitis C]. Zhurnal infektologii [Journal Infectology]. 2014;6(1):67-71. (Russian).

Nabatchikova EA, Abdurakhmanov DT, Nikulkina EN, Rozina TP, Tanaschuk EL, Nikiforova NV, Adonyeva VS, Moiseev SV. Techenie i ishody cirroza pecheni posle jeliminacii virusa gepatita S: rezultaty dolgosrochnogo prospektivnogo nabljudenija [The long-term prospective study of patients with liver cirrhosis after elimination of the hepatitis C virus]. Terapevticheskij arhiv [Therapeutic archive]. 2020;92(2):34-42. https://doi.org/10.26442/00403660.2020.02.000511. (Russian).

Shanytsina SE, Burnevich EZ, Nikulkina EN, Filatova AL, Mukhin NA. Prognosticheskie faktory neblagoprijatnyh ishodov hronicheskogo gepatita C [Prognostic factors of unfavorable outcomes in patients with chronic hepatitis C]. Klinicheskaja farmakologija i terapija. 2018;27(1):27-34. (Russian).

Essa M, Sabry A, Abdelsameea E, Tharwa ES, Salama M. Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis. Eur. J. Gastroenterol. Hepatol. 2019;31(1):53-58. https://doi.org/10.1097/MEG.0000000000001250.

Mangia A, Lawitz E, Gane E, Conway B, Ruane P, Abergel A, Mcnabb B, Osinusi A, Chen F, Dvory-Sobol H, Brainard D, Subramanian M, Leggett B, Panero LC, Agarwal K, Younes ZH, Muir A. Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens. J. Hepatol. 2018;68(Suppl. 1):S67-S68. https://doi.org/10.1016/S0168-8278(18)30356-8.

Gautier SV, Khomyakov SM. Donorstvo i transplantacija organov v Rossijskoj Federacii v 2019 godu. XII soobshhenie registra Rossijskogo transplantologicheskogo obshhestva [Organ donation and transplantation in the Russian Federation in 2019 12™ report from the registry of the russian transplant society]. Vestnik transplantologii i iskusstvennyh organov [Russian journal of transplantology and artificial organs]. 2020;22(2):8-34. https://doi.org/10.15825/1995-1191-2020-2-8-34. (Russian).

Germer JJ, Mandrekar JN, Bendel JL, Mitchell PS, Yao JD. Hepatitis C virus genotypes in clinical specimens tested at a national reference testing laboratory in the United States. J. Clin. Microbiol. 2011;49(8):3040-3043. https://doi.org/10.1128/JCM.00457-11.

Lvov DK, Derjabin PG. Geograficheskoe rasprostranenie virusa gepatita C i ego genotipov. Voprosy virusologii. 1997;(5):196-199. (Russian).

ITPCru. Rezultaty monitoringa zakupok preparatov dlja lechenija gepatita S v Rossii v 2018 godu [Internet]. Available from: https://itpcru.org/2019/07/29/rezultaty-monitorin-ga-zakupok-preparatov-dlya-lecheniya-gepatita-s-v-ros-sii-v-2018-godu/ (Russian).

European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol. 2018;69(2):461-511. https://doi.org/10.1016/j.jhep.2018.03.026.

Ghany MG, Morgan TR; AASLD-IDSA. Hepatitis C guidance 2019 update. J. Hepatology. 2020;71(2):686-721.

World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic HCV infection [Internet]. Geneva: World Health Organization; 2018. Available from: https://apps.who.int/iris/bitstream/handle/10665/273174/9789241550345-eng.pdf?ua=1

Ministerstvo zdravoohranenija Rossijskoj Federacii, Nacionalnoe nauchnoe obshhestvo infekcionistov. Hronicheskij virusnyj gepatit С (HVGS) u vzroslyh. Klinicheskie rekomendacii [Internet]. Available from: https://nnoi.ru/uploads/files/kr380_gepatit_s_2019.pdf (Russian).

Published
2021-01-13
How to Cite
1.
Dzemova AA, Ganchenko RA, Trifonova GF, Esaulenko EV. CHRONIC HEPATITIS C IN THE RUSSIAN FEDERATION AFTER STARTING THE HCV ELIMINATION PROGRAM. journalHandG [Internet]. 2021Jan.13 [cited 2024Jun.13];4(2):165-70. Available from: http://www.pkc.grsmu.by/index.php/journalHandG/article/view/161
Section
Оригинальные исследования
https://uni.sesc.com.br/rajaslot303/slot gacor 2024slot gacor gampang menangslot gacor gampang menang